###begin article-title 0
###xml 80 84 <span type="species:ncbi:10116">Rats</span>
Simvastatin Restores Down-Regulated GATA-6 Expression in Pulmonary Hypertensive Rats
###end article-title 0
###begin p 1
###xml 360 364 <span type="species:ncbi:10116">rats</span>
###xml 481 500 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 671 675 <span type="species:ncbi:10116">rats</span>
###xml 679 683 <span type="species:ncbi:10116">rats</span>
###xml 894 898 <span type="species:ncbi:10116">rats</span>
###xml 1224 1228 <span type="species:ncbi:10116">rats</span>
###xml 1330 1334 <span type="species:ncbi:10116">rats</span>
###xml 1386 1390 <span type="species:ncbi:10116">rats</span>
Vascular smooth muscle cell proliferation has been known to be predominant in vascular remodeling of pulmonary hypertensive. The GATA family proteins, a group of zinc finger transcription factors, play an important role during cell proliferation. The aim of present study was to investigate the expression of GATA-6 gene in experimental pulmonary hypertensive rats and explore the effect of regulation of GATA-6 expression by simvastatin on pulmonary vascular remodeling. The male Sprague-Dawley rats model was established with receiving pneumonectomy and monocrotaline (MCT) administration. Right pulmonary artery remodeling in these animals was compared with untreated rats or rats receiving simvastatin. The level of GATA-6 mRNA and protein expression was detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blotting, respectively. Pneumonectomized, MCT-treated rats had significantly increased mean pulmonary arterial pressure (mPAP), RV/(LV + S) ratio (ratio of the right ventricular to left ventricular and septum weights), vascular occlusion scores (VOSs), and percent media wall thickness on day 35, all the indices were significantly decreased after simvastatin administration in these rats. The level of GATA-6 mRNA and protein were markedly decreased in these pneumonectomy and MCT-treated rats, and they were significantly up-regulated in these rats after receiving simvastatin. These results indicate that the development and progression of pulmonary hypertension is prevented by simvastatin by up-regulating GATA-6 expression in the lung tissue.
###end p 1
###begin p 2
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 1136 1137 1133 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 1139 1140 1136 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
Hypertensive pulmonary vascular disease is characterized by pulmonary vascular remodeling, involving abnormal proliferation of vascular endothelial and smooth muscle cells and extracellular matrix deposition, leading to occlusion of pulmonary arterioles, pulmonary hypertension, right ventricular failure, and death. Pulmonary arterial endothelial cell injury are considered prerequisites for the induction of advanced vascular remodeling in pulmonary arterial hypertension [1-4]. Migration, proliferation, and matrix synthesis of pulmonary artery smooth muscle cells play a key role in pulmonary vascular remodeling. Normal adult pulmonary arterial smooth muscle cells do not migrate, grow, or synthesize matrix once normal development is completed. Dysfunction of endothelium and elevated shear stress may result in smooth muscle cells proliferation, migration, and matrix synthesis. Increase in shear stress due to high flow modulates production of platelet-derived growth factor, transforming growth factor-beta, nitric oxide, and transcription factors of the GATA family that regulate cell growth, migration, and matrix synthesis [5, 6].
###end p 2
###begin p 3
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 495 496 495 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 912 914 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
The GATA family proteins are a group of zinc finger transcription factors that play an important role during mammalian organ morphogenesis, cell proliferation, and sex differentiation [7]. These factors bind to a consensus DNA motif (A/T)GATA(A/G) in the promoters of target genes in a variety of tissues [7]. Six GATA family members have been identified in vertebrates and can be divided into 2 groups based on their tissue distribution and homology: GATA-1, -2, and -3 and GATA-4, -5, and -6 [8]. GATA-1, -2, and -3 genes are predominantly expressed in hematopoietic cells where they are involved in proliferation and differentiation of several cell lineages [9-12]. GATA-4, -5, and -6 are expressed in heart, liver, lungs, and the gastrointestinal tract where they mediate tissue-specific gene expression, and GATA-6 is the only member of the GATA family expressed in vascular smooth muscle cells (VSMCs) [13-17].
###end p 3
###begin p 4
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 1415 1417 1415 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
Analysis of vascular smooth muscle cells has demonstrated an important role of GATA-6 in regulating cell proliferation in response to mitogenic or mechanical stimulation. GATA-6 mRNA levels are down-regulated in proliferating vascular smooth muscle cells, suggesting that GATA-6 expression is linked to the cell cycle in these cells and plays as an important regulator of the VSMC phenotype [18-20]. More specifically, forced expression of GATA-6 in vascular smooth muscle cells induces growth arrest through a mechanism involving enhanced expression of the cyclin-dependent kinase inhibitor p21 [20, 21]. In vivo, adenovirus-mediated gene transfer of GATA-6 in balloon-injured carotid arteries prevented vessel lesions associated with vascular smooth muscle cell phenotypic modulation [21]. Interestingly, laminar shear stress was recently demonstrated to activate transcription factor GATA-6 [22], which binds to a GATA consensus element located in the region of downstream gene promoter regulating these gene expression. A study in vitro reveals that GATA-6 regulates a set of genes associated with synthetic SMC functions and suggests that this transcriptional pathway may be independent from myocardin-induced SMC differentiation in VSMCs. An unbiased microarray screen of genes regulated by GATA-6 in VSMCs identifies that endothelin-1 and angiotensin 1a (AT1a) receptor genes are direct GATA-6 target genes [23]. Based on these studies, we speculate that activity of transcription factor GATA-6 may be regulated by disturbed laminar shear stresses occurring in pulmonary hypertension.
###end p 4
###begin p 5
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 744 747 744 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kip</italic>
###xml 744 748 744 748 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>Kip</italic>1</sup>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 932 934 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 1134 1136 1134 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 1137 1139 1137 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 1370 1372 1366 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 1058 1061 <span type="species:ncbi:10116">rat</span>
The 3-hydroxymethyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, statins, improve cardiovascular outcomes independent of their effects on cholesterol reduction [24]. The immunosuppressive and anti-inflammatory properties of statins [25] may contribute to the improved survival of patients with atherosclerosis [24, 26]. Statins can suppress endothelial and vascular smooth muscle cell proliferative and inflammatory responses to injury [27, 28]. These effects involve inhibition of isoprenylation of Rho and Rac family GTPases that couple growth factor receptors to the intracellular mitogen-activated protein/extracellular signal-regulated kinase (MAP/ERK) kinase signaling pathways and induction of the cell cycle inhibitor p27Kip1 [27, 28]. Statins also improve endothelium-dependent relaxation through mechanisms that involve induction of endothelial nitric oxide synthase (eNOS) and nitric oxide production [29, 30]. Several studies demonstrate that simvastatin, a member of the statin family, attenuates pulmonary vascular remodeling in rat neointimal and hypoxic models of pulmonary arterial hypertension (PAH) [31-33]. Interestingly, simvastatin is recently demonstrated in vitro to induce the expression of smooth muscle alpha-actin (SM-a-actin) and major histocompatibility complex (SM-MHC), highly specific markers of differentiated phenotype [34]. So we speculated whether pleiotropic atheroprotective effects of HMG-CoA reductase inhibitors may be mediated by the expression of other members of GATA family that play an important role in cell proliferation.
###end p 5
###begin p 6
In this study, we used an animal model of pulmonary hypertension by combination of monocrotaline (MCT) administration with pneumonectomy to investigate the efficacy of simvastatin and its mechanism of reversing established neointimal vascular occlusion and pulmonary hypertension. We showed that the expression of GATA-6 mRNA and protein was down-regulated in this pulmonary hypertension model, which was reversed by simvastatin administration.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
Animal Model
###end title 8
###begin p 9
###xml 464 466 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 19 38 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 236 240 <span type="species:ncbi:10116">rats</span>
###xml 479 483 <span type="species:ncbi:10116">rats</span>
###xml 654 658 <span type="species:ncbi:10116">Rats</span>
###xml 735 738 <span type="species:ncbi:10116">rat</span>
Pathogen-free male Sprague-Dawley rats weighing between 300 and 400 g (12 weeks old) were used for this study. All animals were obtained from Sichuan University Animal Centre (Sichuan, Chendu, China) and received humane care. On day 0, rats were anesthetized by an intraperitoneal injection of 10% chloral hydrate (400 mg/kg) and injected subcutaneously atropine sulfate (50 mug/kg) in the right hindlimb. Left pneumonectomy was performed as previously described [35]. On day 7, rats were injected subcutaneously in the nape with monocrotaline (MCT) (60 mg/kg; Sigma, USA). MCT was dissolved in 0.5 N HCl and adjusted to pH 7.4 with 0.5 N NaOH solution. Rats were housed with a 12/12-hour light/dark cycle and given water and standard rat chow ad libitum.
###end p 9
###begin title 10
Treatment Groups
###end title 10
###begin p 11
###xml 167 171 167 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 173 174 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 228 233 228 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 291 295 291 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 377 382 377 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 460 464 460 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 466 467 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 480 484 480 484 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 486 487 486 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 17 21 <span type="species:ncbi:10116">rats</span>
###xml 150 154 <span type="species:ncbi:10116">Rats</span>
###xml 674 678 <span type="species:ncbi:10116">rats</span>
###xml 768 772 <span type="species:ncbi:10116">rats</span>
Pneumonectomized rats were randomized to receive simvastatin or vehicle by daily gavage, or neither simvastatin nor vehicle. Six groups were studied: Rats in group PMV1-35 (n = 12) received a vehicle from days 1 to 35. Group PMV21-35 (n = 12) received a vehicle from days 21 to 35. Group PMS1-35 (n = 12) received simvastatin (2 mg/kg per day) [31] from days 1 to 35. Group PMS21-35 (n = 12) received simvastatin (2 mg/kg per day) from days 21 to 35. Groups PM1-21 (n = 10) and PM1-35 (n = 12) received neither simvastatin nor vehicle, and were sacrificed on day 21 or 35 (post pneumonectomy) to provide reference point for disease progression in this model. Ten additional rats were studied as a control group without any intervention. On day 35 after pneumonectomy, rats were sacrificed and organs harvested for the following analysis.
###end p 11
###begin title 12
Hemodynamic Studies and Tissue Preparation
###end title 12
###begin p 13
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 11 15 <span type="species:ncbi:10116">rats</span>
On day 35, rats were anesthetized with an intraperitoneal injection of 10% chloral hydrate. Mean pulmonary arterial pressures (mPAPs) were measured as previously described [36, 37]. After exsanguination, the right lung, right ventricle, left ventricle, and septum were collected for histology [36, 37]. Tissues were fixed in 10% neutral-buffered formalin, paraffin embedded, and sectioned. After EVG (elastin-van Gieson) staining, lung sections were examined histologically for evidence of pulmonary vascular disease. The severity of pulmonary vascular neointimal formation was assessed in 50 panacinar arteries from each animal. The severity of neointimal formation was expressed as the vascular occlusion score (VOS), which was scored according to the criteria of Okada and coworkers [35]. Briefly, the absence of neointimal formation or luminal occlusion equals grade 0; the presence of neointimal formation causing less than 50% luminal occlusion equals grade 1; the presence of neointimal formation causing greater than 50% luminal occlusion equals grade 2. An average score for 50 vessels (bounded by 0 and 2) was calculated for each animal. Samples of right lung were immediately placed in liquid nitrogen for extraction of total RNA.
###end p 13
###begin title 14
Pulmonary Artery Morphometry
###end title 14
###begin p 15
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
Analysis of each section was carried out in a blinded fashion. To assess the degree of medial thickening of muscular pulmonary arteries, images of 30 to 50 vessels were recorded in subsets of animals at x 400. Each artery was classified by the structure of the accompanying airway as terminal bronchiole, respiratory bronchiole, alveolar duct, or alveolar wall. The software Image-Pro plus, version 4.5.0.29, was used to measure mean arterial diameter (between external elastic laminae) and media thickness (between internal and external elastic laminae) in complete muscular arteries that accompanied terminal and respiratory bronchioles. The percent medial wall thickness (%WT) was expressed as %WT = (media thickness x 2)/external diameter x 100 [38].
###end p 15
###begin title 16
GATA-6 Gene Expression Analysis
###end title 16
###begin title 17
RNA Isolate and RT-PCR
###end title 17
###begin p 18
###xml 322 367 316 361 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="19">GATA-6, forward: 5&#8242;-CCCAGCGCAGACCTGTTGGAGGACC</p>
###xml 322 367 316 361 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="19">GATA-6, forward: 5&#8242;-CCCAGCGCAGACCTGTTGGAGGACC</p></list-item>
###xml 367 409 361 403 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="20">GATA-6, reverse: 5&#8242;-TGTGACAGTTGGCACAGGACAG</p>
###xml 367 409 361 403 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="20">GATA-6, reverse: 5&#8242;-TGTGACAGTTGGCACAGGACAG</p></list-item>
###xml 409 455 403 446 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="21">&#946;&#8211;Actin, forward: 5&#8242;-GACCCAGATCATGTTTGAGACC</p>
###xml 409 455 403 446 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="21">&#946;&#8211;Actin, forward: 5&#8242;-GACCCAGATCATGTTTGAGACC</p></list-item>
###xml 455 501 446 489 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="22">&#946;&#8211;Actin, reverse: 5&#8242;-GCAGTAATCTCCTCCTGCATCC</p>
###xml 455 501 446 489 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="22">&#946;&#8211;Actin, reverse: 5&#8242;-GCAGTAATCTCCTCCTGCATCC</p></list-item>
###xml 322 501 316 489 <list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" list-type="simple"><list-item><p textid="19">GATA-6, forward: 5&#8242;-CCCAGCGCAGACCTGTTGGAGGACC</p></list-item><list-item><p textid="20">GATA-6, reverse: 5&#8242;-TGTGACAGTTGGCACAGGACAG</p></list-item><list-item><p textid="21">&#946;&#8211;Actin, forward: 5&#8242;-GACCCAGATCATGTTTGAGACC</p></list-item><list-item><p textid="22">&#946;&#8211;Actin, reverse: 5&#8242;-GCAGTAATCTCCTCCTGCATCC</p></list-item></list>
###xml 15 18 <span type="species:ncbi:10116">rat</span>
###xml 162 165 <span type="species:ncbi:10116">rat</span>
###xml 290 293 <span type="species:ncbi:10116">rat</span>
Total RNA from rat lung was isolated using Trnzol (Tiantgen, China). Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to amplify portions of the rat GATA-6 gene (GATA-6; GenBank accession number NM019185) and beta-actin (beta-actin; GenBank accession number NM031144) from rat lung. The primers used were GATA-6, forward: 5'-CCCAGCGCAGACCTGTTGGAGGACCGATA-6, reverse: 5'-TGTGACAGTTGGCACAGGACAGbeta-Actin, forward: 5'-GACCCAGATCATGTTTGAGACCbeta-Actin, reverse: 5'-GCAGTAATCTCCTCCTGCATCC Reverse transcription was carried out with 1 mug of total RNA in a reaction volume of 20 muL using ReverTra Ace-a kit (ToYoBo) following the provided instructions. Following the reverse transcription of RNA template, 1 muL of the synthesized cDNA was amplified by PCR. The cycling parameters for each primer pair were analyzed independently in preliminary experiments. The PCR for GATA-6 was conducted at 95degreesC for 2 minutes, 95degreesC for 30 seconds, 61degreesC for 45 seconds, 72degreesC for 45 seconds for 33 cycles, followed by an additional 72degreesC 10 minutes for elongation in the final cycle. The PCR for beta-actin was conducted at 94degreesC for 3 minutes, 94degreesC for 30 seconds, 61degreesC for 30 seconds, 72degreesC for 1 minutes for 30 cycles, followed by an additional 72degreesC 5 minutes for elongation in the final cycle. Finally, the RT-PCR product was analyzed by gel electrophoresis in a 1% agarose gel, stained by ethidium bromide (Sigma, USA) and then visualized under UV (ultraviolet) light. Gel electrophoretic analysis was performed with a UVP GelWorks system (1D Intermediate Version 3.01; USA) to quantify the relative levels of GATA-6 to beta-actin.
###end p 18
###begin p 19
GATA-6, forward: 5'-CCCAGCGCAGACCTGTTGGAGGACC
###end p 19
###begin p 20
GATA-6, reverse: 5'-TGTGACAGTTGGCACAGGACAG
###end p 20
###begin p 21
beta-Actin, forward: 5'-GACCCAGATCATGTTTGAGACC
###end p 21
###begin p 22
beta-Actin, reverse: 5'-GCAGTAATCTCCTCCTGCATCC
###end p 22
###begin title 23
Western Blot Analysis
###end title 23
###begin p 24
###xml 834 839 <span type="species:ncbi:9606">human</span>
###xml 995 1006 <span type="species:ncbi:3704">horseradish</span>
###xml 1029 1033 <span type="species:ncbi:9925">goat</span>
###xml 1039 1045 <span type="species:ncbi:9986">rabbit</span>
Whole-cell lysates were prepared and Western blot analyses were performed to detect GATA-6 protein expression. In brief, 100 mg of lung tissue was homogenated with 1 ml of tissue protein lysis buffer (MT-CelLytics; Biocolors, China). Equivalent amounts of protein (100 mug) were separated by 10% sodium dedecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) minigels for approximately 100 minutes at 200 V to separate the region between 50 and 60 kDa and were electroblotted onto polyvinylidene difluoride transfer membrane (Roche, Germany). Blocked membranes were incubated with polyclonal antibody GATA-6 (Santa Cruz; 1:750) in Tris-buffered saline supplemented with 0.05% of Tween-20 (TTBS) plus 1% nonfat milk overnight at 4degreesC. The GATA-6 antibody recognizes the first 20 amino acids at the C-terminus of recombinant human GATA-6. No blocking peptides are available for these antibodies. Following extensive washing with TTBS, membranes were incubated with a 1:1000 dilution of horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (IgG) secondary antibodies (Santa Cruz; 1:1000) in TTBS plus 5% milk for 1 hour at room temperature. After extensive washing with TTBS, protein-antibody complexes were visualized by the enhanced chemiluminescene detection system (Pierce, USA). Membranes were reprobed for actin (Santa Cruz; 1:2000).
###end p 24
###begin title 25
Statistical Analysis
###end title 25
###begin p 26
###xml 231 232 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Data were expressed as means +/- SD. One-way analysis of variance (ANOVA) was used to compare means between groups and the Newman-Keuls method for post hoc multiple comparisons assuming unequal variances using SPSS13.0 software. A P value of <.05 was taken to indicate that conventional statistical significance had been achieved.
###end p 26
###begin title 27
RESULTS
###end title 27
###begin title 28
Simvastatin Prevented Development of Pulmonary Arterial Hypertension
###end title 28
###begin p 29
###xml 16 20 16 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 97 106 97 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>A</italic></xref>
###xml 140 144 140 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 226 227 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 218 227 218 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>A</italic></xref>
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
###xml 124 128 <span type="species:ncbi:10116">rats</span>
Rats in group PM1-21 gradually developed severe pulmonary arterial hypertension (PAH) by day 21 (Figure 1A). Four out of 12 rats in group PM1-35 died by day 35 and the remainder demonstrated progression to severe PAH (Figure 1A).
###end p 29
###begin p 30
###xml 128 129 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 184 188 184 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 274 278 274 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 347 348 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 414 415 412 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 436 440 434 438 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 447 451 445 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 468 469 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 469 470 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 490 494 488 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 510 514 508 512 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 517 518 515 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 573 577 571 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 591 592 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 603 607 601 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 685 686 683 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 702 706 700 704 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 806 807 804 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 824 829 822 827 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 908 909 906 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 925 930 923 928 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 1031 1032 1029 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1063 1075 1059 1060 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#167;</sup>
###xml 1075 1076 1060 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1097 1101 1082 1086 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 1118 1122 1103 1107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 1126 1127 1111 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1148 1153 1133 1138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 1170 1175 1155 1160 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 1180 1181 1165 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1202 1206 1187 1191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 1223 1228 1208 1213 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 121 125 <span type="species:ncbi:10116">rats</span>
###xml 220 224 <span type="species:ncbi:10116">rats</span>
###xml 310 314 <span type="species:ncbi:10116">rats</span>
###xml 375 379 <span type="species:ncbi:10116">rats</span>
###xml 639 643 <span type="species:ncbi:10116">rats</span>
###xml 738 742 <span type="species:ncbi:10116">rats</span>
###xml 861 865 <span type="species:ncbi:10116">rats</span>
###xml 962 966 <span type="species:ncbi:10116">rats</span>
Simvastatin prevents the development and progression of pulmonary arterial hypertension in pneumonectomized, MCT-treated rats. (A) Mean pulmonary arterial pressures (mPAPs) in group PM1-21 (pneumonectomized, MCT-treated rats that were sacrificed on day 21; n = 10), Group PM1-35 (pneumonectomized, MCT-treated rats that were sacrificed on day 35; n = 8), and control (normal rats; n = 10). Bars are means +/- SD. *P < .001 for groups PM1-21 and PM1-35 versus control; #P < .001 for group PM1-21 versus group PM1-35. (B) Mean pulmonary arterial pressures (mPAPs) in group PM1-35 as stated in A, group PMV1-35 (MCT-treated, pneumonectomized rats that received vehicle from days 1 to 35; n = 9), group PMS1-35 (MCT-treated, pneumonectomized rats that received simvastatin [2 mg/kg per day] from days 1 to 35; n = 12), group PMV21-35 (MCT-treated, pneumonectomized rats that received vehicle from days 21 to 35; n = 8), group PMS21-35 (MCT-treated, pneumonectomized rats that received simvastatin [2 mg/kg per day] from days 21 to 35; n = 10). Bars are means +/- SD. section signP < .001 for group PMS1-35 versus group PMV1-35; **P < .001 for group PMS21-35 versus group PMV21-35; ***P < .001 for Group PMS1-35 versus group PMS21-35.
###end p 30
###begin p 31
###xml 41 45 41 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 124 129 124 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 220 224 220 224 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 231 236 231 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 289 293 289 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 300 305 300 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 339 340 339 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 331 340 331 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>B</italic></xref>
###xml 24 28 <span type="species:ncbi:10116">rats</span>
###xml 107 111 <span type="species:ncbi:10116">rats</span>
###xml 272 276 <span type="species:ncbi:10116">rats</span>
All simvastatin-treated rats in group PMS1-35 survived the entire course of the study (35 days). Two of 12 rats in group PMS21-35 died by day 35. Simvastatin delayed or partly reversed PAH and decreased mPAP in group PMS1-35 or PMS21-35, compared with the vehicle-treated rats in group PMV1-35 or PMV21-35 on day 35, respectively (Figure 1B).
###end p 31
###begin title 32
Right Ventricular Hypertrophy
###end title 32
###begin p 33
###xml 278 279 278 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 270 279 270 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2<italic>A</italic></xref>
###xml 34 38 <span type="species:ncbi:10116">rats</span>
###xml 209 213 <span type="species:ncbi:10116">rats</span>
###xml 264 268 <span type="species:ncbi:10116">rats</span>
By day 35, pulmonary hypertensive rats demonstrated significant right ventricular hypertrophy. The ratio of the right ventricular to left ventricular and septum weights, RV/(LV + S), of pulmonary hypertensive rats significantly increased in comparison with normal rats (Figure 2A).
###end p 33
###begin p 34
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 293 294 293 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 285 294 285 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>A</italic></xref>
###xml 320 321 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 342 346 340 344 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 353 357 351 355 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 374 375 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 375 376 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 396 400 394 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 416 420 414 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 423 424 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 504 505 502 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 496 505 494 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>B</italic></xref>
###xml 530 542 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#167;</sup>
###xml 542 543 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 564 568 549 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 585 589 570 574 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 593 594 578 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 615 620 600 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 637 642 622 627 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 647 648 632 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 669 674 654 659 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 690 694 675 679 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 119 123 <span type="species:ncbi:10116">rats</span>
###xml 267 271 <span type="species:ncbi:10116">rats</span>
###xml 478 482 <span type="species:ncbi:10116">rats</span>
Simvastatin prevents the development and progression of right ventricular hypertrophy in pneumonectomized, MCT-treated rats. (A) Ratios of right vertricular weight to left ventricular and inter-ventricular septal weights [RV/(LV + S)] are shown among the 3 groups of rats as stated in Figure 1A. Bars are means +/- SD. *P < .001 for groups PM1-21 and PM1-35 versus control; #P < .001 for group PM1-35 versus group PM1-21. (B) Ratios of RV/(LV + S) are shown for the 5 groups of rats as stated in Figure 1B. Bars are means +/- SD. section signP < .001 for group PMS1-35 versus group PMV1-35; **P < .001 for group PMS21-35 versus group PMV21-35; ***P < .001 for group PMS21-35 versus group PM1-35.
###end p 34
###begin p 35
###xml 139 143 139 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 151 156 151 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 190 199 190 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2<italic>B</italic></xref>
###xml 225 229 225 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 237 242 237 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 266 267 266 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 258 267 258 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2<italic>B</italic></xref>
###xml 108 112 <span type="species:ncbi:10116">rats</span>
Simvastatin prevented progression and partly reversed established right ventricular hypertrophy of diseased rats on day 35, with groups PMS1-35 and PMS21-35 showing lower RV/(LV + S) ratio (Figure 2B) compared with groups PMV1-35 and PMV21-35, respectively (Figure 2B).
###end p 35
###begin title 36
Simvastatin Decreased Medial Hypertrophy
###end title 36
###begin p 37
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 110 111 110 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 97 111 97 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3<italic>A</italic> to <italic>F</italic></xref>
###xml 174 178 174 178 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 185 189 185 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 264 265 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 256 265 256 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4<italic>A</italic></xref>
###xml 91 95 <span type="species:ncbi:10116">rats</span>
###xml 157 161 <span type="species:ncbi:10116">rats</span>
Prominent medial wall hypertrophy was evident in muscular pulmonary arteries from diseased rats (Figure 3A to F). The percent medial wall thickness (%WT) of rats in groups PM1-21 and PM1-35 was significantly higher than that of respective control animals (Figure 4A).
###end p 37
###begin p 38
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 128 129 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 134 138 134 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 141 142 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 147 152 147 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 155 156 155 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 160 164 160 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 167 168 167 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 173 177 173 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 180 181 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 186 191 186 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 312 316 312 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 324 329 324 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 108 112 <span type="species:ncbi:10116">rats</span>
Simvastatin prevents the development of small pulmonary artery hypertrophy in pneumonectomized, MCT-treated rats. (A) Control; (B) PMV1-35; (C) PMV21-35; (D) PM1-35; (E) PMS1-35; (F) PMS21-35. Elastin-van Gieson staining (magnification, x 200) images show reduced small pulmonary artery hypertrophy in Groups PMS1-35 and PMS21-35.
###end p 38
###begin p 39
###xml 242 243 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 332 333 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 324 333 323 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>A</italic></xref>
###xml 359 360 356 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 381 385 378 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 392 396 389 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 413 414 410 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 414 415 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 435 439 432 436 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 455 459 452 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 462 463 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 552 553 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 544 553 541 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>B</italic></xref>
###xml 678 690 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#167;</sup>
###xml 690 691 674 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 712 716 696 700 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 733 737 717 721 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 739 753 723 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#9652;</sup>
###xml 753 754 724 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 775 780 746 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 797 802 768 773 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 814 818 785 789 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 887 892 858 863 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 897 898 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 109 113 <span type="species:ncbi:10116">rats</span>
###xml 306 310 <span type="species:ncbi:10116">rats</span>
###xml 526 530 <span type="species:ncbi:10116">rats</span>
###xml 672 676 <span type="species:ncbi:10116">rats</span>
Reduced percent medial wall thickness of small pulmonary artery hypertrophy in pneumonectomized, MCT-treated rats by simvastatin. Small pulmonary artery (50 to 150 mum) hypertrophy measured by (2 x medial thickness/external diameter) x 100. (A) Percent medial wall thickness is shown among the 3 groups of rats as stated in Figure 1A. Bars are means +/- SD. *P < .001 for Groups PM1-21 and PM1-35 versus control; #P < .001 for group PM1-35 versus group PM1-21. (B) Percent medial wall thickness is shown among the 5 groups of rats as stated in Figure 1B. Bars are means +/- SD. Simvastatin alleviated arterial medial hypertrophy in pneumonectomized, monocrotaline-treated rats (section signP < .001 for group PMS1-35 versus group PMV1-35; black triangleP < .001 for group PMS21-35 versus group PMV21-35). Group PMS1-35 had significantly lower percent medial wall thickness than group PMS21-35 (***P < .05).
###end p 39
###begin p 40
###xml 54 58 54 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 66 71 66 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 136 145 136 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4<italic>B</italic></xref>
###xml 193 198 193 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 206 210 206 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 257 266 257 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4<italic>B</italic></xref>
###xml 13 17 <span type="species:ncbi:10116">rats</span>
###xml 156 160 <span type="species:ncbi:10116">rats</span>
In contrast, rats treated with simvastatin (groups PMS1-35 and PMS21-35) demonstrated decreased medial hypertrophy at different degree (Figure 4B), whereas rats treated with vehicle (groups PMV21-35 and PMV1-35) demonstrated significant medial hypertrophy (Figure 4B).
###end p 40
###begin title 41
Histopathology
###end title 41
###begin p 42
###xml 92 96 92 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 101 105 101 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 110 115 110 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 120 124 120 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 133 138 133 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 230 231 230 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 222 236 222 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5<italic>A</italic> to <italic>F</italic></xref>
###xml 366 367 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 358 367 358 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5<italic>G</italic></xref>
###xml 494 495 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 499 500 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 486 500 486 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5<italic>A</italic> to <italic>F</italic></xref>
###xml 629 630 629 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 638 639 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 621 639 621 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5<italic>B</italic> versus <italic>A</italic></xref>
###xml 690 694 690 694 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 702 707 702 707 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 786 790 786 790 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 805 806 805 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 811 812 811 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 820 821 820 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 797 821 797 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5<italic>C</italic> and <italic>D</italic> versus <italic>B</italic></xref>
###xml 949 953 949 953 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 961 966 961 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 978 982 978 982 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 990 995 990 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 1035 1036 1035 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 1027 1036 1027 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5<italic>G</italic></xref>
###xml 66 70 <span type="species:ncbi:10116">rats</span>
###xml 75 79 <span type="species:ncbi:10116">rats</span>
###xml 339 342 <span type="species:ncbi:10116">rat</span>
###xml 537 541 <span type="species:ncbi:10116">rats</span>
###xml 791 795 <span type="species:ncbi:10116">rats</span>
Representative morphologies of small pulmonary arteries in normal rats and rats in groups PM1-35, PMV1-35, PMV21-35, PMS1-35, and PMS21-35 are shown to be stained for elastin-van Gieson to reveal the inner elastin lamina (Figure 5A to F). A quantitative analysis of luminal obstruction on 50 consecutive small pulmonary arteries from each rat was performed (Figure 5G). The distribution of the vascular lesions, and an average vascular occlusion score (between 0 and 2), are presented (Figure 5A to F). The pneumonectomized, MCT-treated rats resulted in severe changes of neointimal proliferation and vascular occlusion (Figure 5B versus A). The vascular occlusion score (VOS) in groups PMV1-35 and PMV21-35 was similar to an average VOS for our laboratory's historical data on group PM1-35 rats (Figure 5C and D versus B). This suggests that the treatment of vehicle does not alter the histopathology of this disease model. Compared with groups PMV1-35 and PMV21-35, groups PMS1-35 and PMS21-35 had a lower VOS, respectively (Figure 5G).
###end p 42
###begin p 43
###xml 186 187 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 277 278 277 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 280 281 280 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 287 288 287 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 354 358 354 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 363 367 363 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 376 381 376 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 384 385 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 430 435 430 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 438 439 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 504 508 504 508 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 582 583 582 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 655 656 655 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 661 662 661 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 647 662 647 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>A</italic> and <italic>B</italic></xref>
###xml 665 666 665 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 686 690 686 690 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 708 709 708 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 730 734 730 734 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 751 755 751 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 758 759 758 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 780 785 780 785 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 802 807 802 807 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 810 811 810 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 832 836 832 836 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 853 858 853 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 196 199 <span type="species:ncbi:10116">rat</span>
###xml 629 633 <span type="species:ncbi:10116">rats</span>
Simvastatin suppresses the development of pulmonary arterial neointimal formation. The vascular occlusion score (VOS) was the average of 50 consecutive intra-acinar pulmonary arteries. (A) Normal rat intra-acinar artery without evidence of neointimal proliferation (grade 0). (B, C, and D) Grade 2 neointimal lesions (>50% luminal occlusion) in groups PM1-35, PMV1-35, and PMV21-35. (E) Predominance of grade 2 lesson in group PMS21-35. (F) Grade 1 neointimal lesion (<50% lumenal occlusion) in group PMS1-35. All samples were stained with EVG. The images are x 400 magnification. (G) Average grades of VOS among the 6 groups of rats as stated in Figure 1A and B. *P < .001 for group PM1-35 versus control; *P < .001 for group PMS1-35 versus group PMV1-35; *P < .001 for group PMS21-35 versus group PMV21-35; *P < .001 for group PMS1-35 versus group PMS21-35, respectively.
###end p 43
###begin title 44
GATA-6 Gene Expression in the Lung Tissue
###end title 44
###begin p 45
###xml 91 92 91 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 83 92 83 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6<italic>A</italic></xref>
###xml 214 218 211 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 225 229 222 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 260 261 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 252 261 249 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6<italic>B</italic></xref>
###xml 373 374 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 365 374 362 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Figure 6<italic>C</italic></xref>
###xml 199 203 <span type="species:ncbi:10116">rats</span>
###xml 246 250 <span type="species:ncbi:10116">rats</span>
###xml 359 363 <span type="species:ncbi:10116">rats</span>
Changes in lung GATA-6 mRNA expression were assessed semiquantitatively by RT-PCR (Figure 6A). The expression of GATA-6 mRNA, normalized to beta-actin expression, was significantly lower in diseased rats (groups PM1-21 and PM1-35) than in normal rats (Figure 6B). Simvastatin treatment increased the expression of GATA-6 mRNA in MCT-treated, pneumonectomized rats (Figure 6C).
###end p 45
###begin p 46
###xml 158 159 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 276 277 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 282 283 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 268 283 265 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>A</italic> and <italic>B</italic></xref>
###xml 286 287 283 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 390 391 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 382 391 376 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>A</italic></xref>
###xml 482 483 473 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 497 498 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 519 523 510 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 530 534 521 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 551 552 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 552 553 543 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 572 576 563 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 592 596 583 587 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 599 600 590 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 703 704 691 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 695 704 683 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>B</italic></xref>
###xml 795 796 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 878 879 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 900 904 885 889 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 921 925 906 910 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 927 939 912 913 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#167;</sup>
###xml 939 940 913 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 961 966 935 940 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 983 988 957 962 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 1000 1004 974 978 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 1073 1078 1047 1052 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 1083 1084 1057 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 118 122 <span type="species:ncbi:10116">rats</span>
###xml 236 239 <span type="species:ncbi:10116">rat</span>
###xml 367 371 <span type="species:ncbi:10116">rats</span>
###xml 680 684 <span type="species:ncbi:10116">rats</span>
###xml 870 874 <span type="species:ncbi:10116">rats</span>
Reduction in GATA-6 mRNA expression during the development of pulmonary hypertension in pneumonectomized, MCT-treated rats that was reversed by simvastatin. (A) RT-PCR analysis of GATA-6 and beta-actin gene expression in representative rat lungs from groups stated in Figure 1A and B. (B) Relative abundance of GATA-6/beta-actin mRNA expression among the 3 groups of rats stated in Figure 1A. Mean and standard deviation of GATA-6 mRNA expression normalized to beta-actin is shown (n = 3/group). *P < .001 for groups PM1-21 and PM1-35 versus control; #P < .01 for group PM1-35 versus group PM1-21. (C) Relative abundance of GATA-6/beta-actin mRNA expression among the 5 groups of rats stated in Figure 1B. Mean and standard deviation of GATA-6 mRNA expression normalized to beta-actin is shown (n = 3/group). Simvastatin restored GATA6 mRNA expression level in diseased rats (**P < .001 for group PMS1-35 versus group PMV1-35; section signP < .001 for group PMS21-35 versus group PMV21-35). Group PMS1-35 had significantly higher GATA-6 mRNA expression level than Group PMS21-35 (***P < .01).
###end p 46
###begin p 47
###xml 94 95 94 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 86 95 86 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7<italic>A</italic></xref>
###xml 168 169 168 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 160 169 160 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7<italic>A</italic></xref>
###xml 225 229 225 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 236 240 236 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 296 297 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 288 297 288 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7<italic>B</italic></xref>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 373 382 373 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Figure 7<italic>C</italic></xref>
###xml 193 197 <span type="species:ncbi:10116">rats</span>
###xml 208 212 <span type="species:ncbi:10116">rats</span>
The lung expression of GATA-6 protein was assessed qualitatively by Western blotting (Figure 7A). A GATA-6 antiserum-immunoreactive band is detected at 56 kDa (Figure 7A). Compared with normal rats, diseased rats in groups PM1-21 and PM1-35 showed decreased expression of GATA-6 protein (Figure 7B). Simvastatin treatment significantly increased GATA-6 protein expression (Figure 7C).
###end p 47
###begin p 48
###xml 160 161 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 299 300 299 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 305 306 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 291 306 291 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>A</italic> and <italic>B</italic></xref>
###xml 309 310 309 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 420 421 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 412 421 409 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>A</italic></xref>
###xml 515 516 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 530 531 524 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 551 555 545 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 574 575 568 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 594 598 588 592 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 615 616 609 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 616 617 610 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 636 640 630 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 656 660 650 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;21</sub>
###xml 663 664 657 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 770 771 761 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 762 771 753 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1<italic>B</italic></xref>
###xml 865 866 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 953 954 941 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 975 979 963 967 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 996 1000 984 988 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 1002 1014 990 991 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#167;</sup>
###xml 1014 1015 991 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1036 1041 1013 1018 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 1058 1063 1035 1040 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 1075 1079 1052 1056 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1&#8211;35</sub>
###xml 1151 1156 1128 1133 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">21&#8211;35</sub>
###xml 1162 1163 1139 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 120 124 <span type="species:ncbi:10116">rats</span>
###xml 236 239 <span type="species:ncbi:10116">rat</span>
###xml 397 401 <span type="species:ncbi:10116">rats</span>
###xml 747 751 <span type="species:ncbi:10116">rats</span>
###xml 944 948 <span type="species:ncbi:10116">rats</span>
Decrease in GATA-6 protein expression during the development of pulmonary hypertension in pneumonectomized, MCT-treated rats that was restored by simvastatin. (A) Western blotting analysis of GATA-6 protein expression in representative rat lung protein extracts from each group as stated in Figure 1A and B. (B) Relative abundance of GATA-6/beta-actin protein expression among the three groups of rats stated in Figure 1A. Mean and standard deviation of GATA-6 protein expression normalized to beta-actin is shown (n = 3/group). *P < .001 for group PM1-35 versus control; **P < .01 for group PM1-21 versus control; #P < .01 for group PM1-35 versus group PM1-21. (C) Relative abundance of GATA-6/beta-actin protein expression among the 5 groups of rats stated in Figure 1B. Mean and standard deviation of GATA-6 protein expression normalized to beta-actin is shown (n = 3/group). Simvastatin restored GATA-6 protein expression level in diseased rats (***P < .001 for group PMV1-35 versus group PMS1-35; section signP < .001 for group PMV21-35 versus group PMS21-35). Group PMS1-35 had significantly higher GATA-6 protein expression level than group PMS21-35 (****P < .01).
###end p 48
###begin title 49
DISCUSSION
###end title 49
###begin p 50
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 1253 1255 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40</xref>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">43</xref>
Pulmonary arterial hypertension is characterized histopathologically by changes of abnormal proliferation of vascular endothelial and smooth muscle cells, occlusion of microvascular pulmonary arteries, and plexiform lesion formation in severe cases. Although the pathogenesis of most forms of pulmonary arterial hypertension is unknown, there have been many recent developments in pathogenesis involving inappropriate proliferation and constriction of vascular smooth muscle cells, and deficiencies of endogenous vasodilators such as prostacyclin and endothelial-derived nitric oxide [39], especially pertaining to the molecular genetics and cell biology of idiopathic pulmonary arterial hypertension. The increase in pulmonary arterial pressure leads to right ventricular congestive failure and ultimately to death. Current treatment strategies for PAH include diuretics, anticoagulation, digoxin, and supplemental oxygen for congestive heart failure, and pulmonary vasodilating agents such as calcium channel antagonists and prostanoids, especially intravenous (IV) epoprostenol and endothelin-receptor antagonists. New therapies, especially theose directing at suppressing inappropriate neointimal proliferation in pulmonary arteries, are warranted [40-43].
###end p 50
###begin p 51
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 836 838 836 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">47</xref>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Statins, the HMG CoA reductase inhibitors, have had a dramatic impact on clinical outcomes in patients with coronary artery disease. Several studies have documented benefits unrelated to cholesterol lowering [44, 45], with multiple "pleiotropic" effects on vascular wall function that would be expected to attenuate vascular remodeling [46]. These effects stem from their ability to reduce the production of the isoprenoid intermediates farnesyl and geranylgeranyl pyrophosphate, compounds that are distal to mevalonate in the cholesterol synthetic pathway. These lipophilic molecules are then covalently bound to Rho and other small G proteins in a post-translational modification that is essential for attachment of these important signaling proteins to cell membranes and regulators and for their activation of downstream effectors [47].
###end p 51
###begin p 52
###xml 124 127 <span type="species:ncbi:10116">rat</span>
###xml 515 519 <span type="species:ncbi:10116">rats</span>
###xml 732 736 <span type="species:ncbi:10116">rats</span>
In present study, we probed the hypothesis that statins could attenuate vascular remodeling and pulmonary hypertension in a rat model of neointimal pulmonary hypertension. Simvastatin administration produced a marked reduction in pulmonary artery pressure developed in animals with pneumonectomy and MCT administration. Simvastatin also significantly reduced the right ventricular hypertrophy, as indicated by the RV/(LV + S) weight ratio. Morphological analysis of the pulmonary vasculature of simvastatin-treated rats revealed considerable decrease in medial thickness of medium-sized arteries and neointimal formation. We also found that GATA-6 mRNA and protein expression dramatically decreased in pneumonectomized, MCT-treated rats that was restored by simvastatin administration.
###end p 52
###begin p 53
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 725 727 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 996 998 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">48</xref>
###xml 1109 1111 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">49</xref>
###xml 1133 1135 1129 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">50</xref>
###xml 1162 1164 1158 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">51</xref>
###xml 1441 1445 1437 1441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">kip1</sup>
###xml 1502 1504 1498 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 1611 1613 1607 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 1670 1672 1666 1668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">52</xref>
###xml 1775 1777 1771 1773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 1832 1834 1828 1830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">53</xref>
###xml 270 274 <span type="species:ncbi:10116">rats</span>
###xml 414 418 <span type="species:ncbi:10116">rats</span>
The exact mechanism of attenuation of neointimal pulmonary hypertension by simvastatin was not understood. Several actions of statins could account for our observations. Statins have been noted to reduce blood pressure in spontaneously hypertensive but not normotensive rats [38]. Simvastatin treatment potently inhibits vascular remodeling by attenuates chronic hypoxic pulmonary hypertension and polycythemia in rats [33], and reverses pulmonary arterial neointimal formation and PAH after toxic injury by down-regulating the inflammatory genes fos, jun, and tumor necrosis factor-alpha and up-regulating the cell cycle inhibitor p27Kip1, endothelial nitric oxide synthase, and bone morphogenetic protein receptor type 1a [31]. Inhibition of HMG-CoA reductase by statins decreases isoprenoid intermediates such as farnesyl-PP and geranylgeranyl-PP, which leads to an inhibition of isoprenylation of small GTPases such as Ras, Rho, Rab, and Rap. Among the Rho GTPases are RhoA, Rac1, and Cdc42 [48]. Statins have been shown to induce apoptosis of pulmonary vascular smooth muscle cells in serum-free medium [49]. Both endothelin-1 [50] and endothelin receptor [51] transcriptions are reduced by statins, which would attenuate chronic hypoxic pulmonary hypertension. Simvastatin markedly decreased the platelet-derived growth factor-induced proliferation of vascular smooth muscle cells by preventing Rho GTPase-induced downregulation of p27kip1, an important negative regulator of cell proliferation [28]. Simvastatin is also demonstrated to regulate the differentiation and the phenotype expression of VSMCs [34]. In addition, statins have potent antioxidant effects [52]. Given that oxidative stress may be an important mediator of chronic hypoxic pulmonary hypertension [38] as well as acute hypoxic pulmonary vasoconstriction [53], the antioxidant effect of simvastatin may also play a role in attenuation of pulmonary hypertension observed here.
###end p 53
###begin p 54
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">54</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">55</xref>
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
In this study, we found that down-regulation of GATA-6 expression was concurrent with development and progression of pulmonary hypertension, right ventricular hypertrophy, arterial medial hypertrophy, and neointimal formation in the neointimal pulmonary hypertensive model. GATA-6 gene expression has been detected in the pericardial mesoderm, embryonic heart tube, and primitive gut during early embryonic development [54]. However, during development, GATA-6 becomes the only member of the family expressed in vascular smooth muscle cells [15, 55] and its expression is down-regulated in proliferating vascular smooth muscle cells [18]. These data suggest that down-regulation of GATA-6 expression is closely associated with pulmonary arterial smooth muscle cells proliferation and that the level of GATA-6 expression may be an indicator of severity of hypertensive pulmonary vascular disease.
###end p 54
###begin p 55
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">56</xref>
###xml 355 359 <span type="species:ncbi:10116">rats</span>
###xml 648 653 <span type="species:ncbi:9606">human</span>
###xml 654 662 <span type="species:ncbi:9606">patients</span>
Some recent reports show that simvastatin up-regulates GATA-3 expression in dendritic cells and up-regulates the binding activity of GATA-6 to SM-MHC GATA site, whereas mutating the GATA-6 binding site abolished this activation [34, 56]. In the present study, we also found that down-regulation of GATA-6 expression was reversed in pulmonary hypertensive rats treated with simvastatin. However, the precise mechanism that statins regulate expression of GATA family members is unknown. Further studies will be performed to investigate the mechanism of GATA-6 expression by regulated by simastatin and examine GATA-6 expression in the lung tissue of human patients with pulmonary hypertension.
###end p 55
###begin p 56
This work was supported in part by a grant from the National Natural Science Foundation of China (30300145).
###end p 56
###begin title 57
Declaration of interest
###end title 57
###begin p 58
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
###end p 58
###begin title 59
REFERENCES
###end title 59
###begin article-title 60
Endothelial dysfunction in pulmonary hypertension
###end article-title 60
###begin article-title 61
Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension
###end article-title 61
###begin article-title 62
The role of increased pulmonary blood flow in pulmonary arterial hypertension
###end article-title 62
###begin article-title 63
Cellular and molecular mechanisms of pulmonary vascular remodeling
###end article-title 63
###begin article-title 64
###xml 100 105 <span type="species:ncbi:9606">human</span>
Differential regulation of urokinase-type plasminogen activator expression by fluid shear stress in human coronary artery endothelial cells
###end article-title 64
###begin article-title 65
Flow-mediated endothelial mechanotransduction
###end article-title 65
###begin article-title 66
GATA-binding transcription factors in hematopoietic cells
###end article-title 66
###begin article-title 67
The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression
###end article-title 67
###begin article-title 68
Transcription factor GATA-3 is required for development of the T-cell lineage
###end article-title 68
###begin article-title 69
###xml 34 38 <span type="species:ncbi:10090">mice</span>
An early haematopoietic defect in mice lacking the transcription factor GATA-2
###end article-title 69
###begin article-title 70
Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1
###end article-title 70
###begin article-title 71
Transcription factor GATA-1 in megakaryocyte development
###end article-title 71
###begin article-title 72
The GATA family (vertebrates and invertebrates)
###end article-title 72
###begin article-title 73
GATA6 regulates differentiation of distal lung epithelium
###end article-title 73
###begin article-title 74
GATA-6: a zinc finger transcription factor that is expressed in multiple cell lineages derived from lateral mesoderm
###end article-title 74
###begin article-title 75
Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts
###end article-title 75
###begin article-title 76
GATA6 is essential for embryonic development of the liver but dispensable for early heart formation
###end article-title 76
###begin article-title 77
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human GATA-6 gene: structure, chromosomal location, and regulation of expression by tissue-specific and mitogen-responsive signals
###end article-title 77
###begin article-title 78
GATA-6 induces p21 (Cip1) expression and G1 cell cycle arrest
###end article-title 78
###begin article-title 79
###xml 125 128 <span type="species:ncbi:10116">rat</span>
Reversal of GATA-6 downregulation promotes smooth muscle differentiation and inhibits intimal hyperplasia in balloon-injured rat carotid artery
###end article-title 79
###begin article-title 80
GATA-6: the proliferation stops here: cell proliferation in glomerular mesangial and vascular smooth muscle cells
###end article-title 80
###begin article-title 81
###xml 100 105 <span type="species:ncbi:9606">human</span>
Differential regulation of urokinase-type plasminogen activator expression by fluid shear stress in human coronary artery endothelial cells
###end article-title 81
###begin article-title 82
GATA-6 regulates genes promoting synthetic functions in vascular smooth muscle cells
###end article-title 82
###begin article-title 83
Current perspectives on statins
###end article-title 83
###begin article-title 84
Statins as a newly recognized type of immunomodulator
###end article-title 84
###begin article-title 85
###xml 82 88 <span type="species:ncbi:9986">rabbit</span>
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis
###end article-title 85
###begin article-title 86
Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury
###end article-title 86
###begin article-title 87
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)
###end article-title 87
###begin article-title 88
Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
###end article-title 88
###begin article-title 89
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
###end article-title 89
###begin article-title 90
###xml 20 24 <span type="species:ncbi:10116">rats</span>
Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells
###end article-title 90
###begin article-title 91
###xml 92 96 <span type="species:ncbi:10116">rats</span>
Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats
###end article-title 91
###begin article-title 92
Attenuation of chronic hypoxic pulmonary hypertension by simvastatin
###end article-title 92
###begin article-title 93
Statins activate GATA-6 and induce differentiated vascular smooth muscle cells
###end article-title 93
###begin article-title 94
###xml 34 37 <span type="species:ncbi:10116">rat</span>
Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension
###end article-title 94
###begin article-title 95
###xml 82 86 <span type="species:ncbi:10116">rats</span>
Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats
###end article-title 95
###begin article-title 96
###xml 3 4 3 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 103 107 <span type="species:ncbi:10116">rats</span>
40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats
###end article-title 96
###begin article-title 97
Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia
###end article-title 97
###begin article-title 98
Mechanisms of proliferative and obliterative vascular diseases. Insights from the pulmonary and systemic circulations. NHLBI Workshop summary
###end article-title 98
###begin article-title 99
Hypertensive pulmonary vascular disease: dawn of the age of prevention?
###end article-title 99
###begin article-title 100
Emerging therapies for pulmonary hypertension: striving for efficacy and safety
###end article-title 100
###begin article-title 101
Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents
###end article-title 101
###begin article-title 102
Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop
###end article-title 102
###begin article-title 103
Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention
###end article-title 103
###begin article-title 104
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Withdrawal of statins increases event rates in patients with acute coronary syndromes
###end article-title 104
###begin article-title 105
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function
###end article-title 105
###begin article-title 106
Small GTP-binding proteins
###end article-title 106
###begin article-title 107
Rho GTPases, statins, and nitric oxide
###end article-title 107
###begin article-title 108
Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells
###end article-title 108
###begin article-title 109
Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells
###end article-title 109
###begin article-title 110
Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin
###end article-title 110
###begin article-title 111
Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin
###end article-title 111
###begin article-title 112
###xml 93 99 <span type="species:ncbi:9986">rabbit</span>
NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs
###end article-title 112
###begin article-title 113
###xml 70 75 <span type="species:ncbi:10090">mouse</span>
Regulatory elements directing gut expression of the GATA6 gene during mouse early development
###end article-title 113
###begin article-title 114
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
The gene for transcription factor GATA-6 resides on mouse chromosome 18 and is expressed in myocardium and vascular smooth muscle
###end article-title 114
###begin article-title 115
Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells
###end article-title 115

